ArticleThe oncologist2026
Overweight BMI compromises survival and correlates with aggressive phenotypes in early-onset but not late-onset rectal cancer patients.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe incidence of early-onset colorectal cancer (EOCRC) is rising globally, presenting unique clinical challenges due to its aggressive nature compared to late-onset cases. While obesity is a known risk factor for carcinogenesis, its prognostic significance specifically on the EOCRC population remains underexplored. We hypothesized that the association of metabolic dysregulation with tumor aggressiveness and survival may depend on the age of onset.
methodsA total of 324 patients with stage II/III rectal cancer from the FOWARC trial were stratified by BMI (using the Asian overweight cut-off of 24 kg/m2) and age of onset (early-onset <50 years vs. late-onset ≥50 years). The clinicopathologic characteristics, treatment response, complications, and survival outcomes were compared.
resultsThe prognostic profile was heterogeneous between patients with high and low BMI. Notably, age had opposing prognostic value in the two groups. In the early-onset subgroups, patients with high BMI exhibited more prevalent aggressive phenotypes, including T4 stage, MRF+, elevated tumor length/thickness, and pretreatment CEA. However, in the late-onset subgroups, those phenotypes were less in the patients with high BMI. For short-term outcome, the incidence of pathological complete response after neoadjuvant treatment and complications was similar between two groups. In the early-onset subgroups, the overall (P = .003) and disease-free (P = .001) survival outcomes were significantly worse in the patients with high BMI compared to those with low BMI. However, this difference was not observed in the late-onset subgroups.
conclusionThe association of overweight and obesity with aggressive tumor phenotypes and poor survival outcomes is specifically observed in early-onset rectal cancer, which highlights the need for BMI-specific therapeutic strategies and weight management interventions in these vulnerable cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.